Anti-Estrogen Receptor Beta2 [57/3]

Cat. #153632

Anti-Estrogen Receptor Beta2 [57/3]

Cat. #: 153632

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 10-12 weeks

Target: Estrogen Receptor ? 2

Class: Monoclonal

Application: IHC ; IF ; WB

Reactivity: Human

Host: Mouse


This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.


Institute: BioServ UK Ltd

Tool Details
Target Details

Tool Details


  • Name: Anti-Estrogen Receptor Beta2 [57/3]
  • Alternate name: Estrogen receptor beta, ER-beta, Nuclear receptor subfamily 3 group A member 2
  • Clone: 57/3
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Molecular weight: 53 kDa
  • Strain: Balb/c
  • Reactivity: Human
  • Host: Mouse
  • Application: IHC ; IF ; WB
  • Description: Estrogen receptors are commonly over-expressed in cancers. Clone 57/3 recognizes Estrogen Receptor Beta (ERÎ?) 2 and is useful in determining the expression of ERÎ?2 in cancer cells via various analysis methods.
  • Immunogen: Recognizes ER?2 isomer at sequence CGMKMETLLPEATMEQ
  • Isotype: IgG1
  • Myeloma used: Sp2/0-Ag14
  • Recommended controls: Ovary

Target Details

  • Target: Estrogen Receptor ? 2
  • Molecular weight: 53 kDa
  • Tissue cell line specificity: Ovary
  • Target background: Estrogen receptors are commonly over-expressed in cancers. Clone 57/3 recognizes Estrogen Receptor Beta (ER?) 2 and is useful in determining the expression of ER?2 in cancer cells via various analysis methods.


  • Application: IHC ; IF ; WB


  • Format: Liquid
  • Unit size: 100 ug
  • Shipping conditions: Shipping at 4° C


  • Buttarelli et al. 2017. Gynecol Oncol. 145(2):352-360. PMID: 28228232.
  • Hormone receptor expression profile of low-grade serous ovarian cancers.
  • Zannoni et al. 2016. Histopathology. 68(4):541-8. PMID: 26132417.
  • Sexual dimorphism in medulloblastoma features.
  • Gender effect in experimental models of human medulloblastoma: does the estrogen receptor ? signaling play a role?
  • Ciucci et al. 2014. PLoS One. 9(7):e101623. PMID: 25000562.
  • Collins et al. 2009. BMC Cancer. 9:330. PMID: 19758455.
  • Expression of oestrogen receptors, ERalpha, ERbeta, and ERbeta variants, in endometrial cancers and evidence that prostaglandin F may play a role in regulating expression of ERalpha.
  • Carpino et al. 2007. Eur J Endocrinol. 157(2):239-44. PMID: 17656605.
  • Detection of aromatase and estrogen receptors (ERalpha, ERbeta1, ERbeta2) in human Leydig cell tumor.
  • Skliris et al. 2006. Br J Cancer. 95(5):616-26. PMID: 16880783.
  • Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours.
  • Wong et al. 2005. J Pathol. 207(1):53-60. PMID: 15954165.
  • ERbeta isoform expression in colorectal carcinoma: an in vivo and in vitro study of clinicopathological and molecular correlates.
  • Sierens et al. 2004. J Mol Endocrinol. 32(3):703-18. PMID: 15171710.
  • Cloning of oestrogen receptor beta from Old and New World primates: identification of splice variants and Fn analysis.
  • Critchley et al. 2002. J Clin Endocrinol Metab. 87(11):5265-73. PMID: 12414901.
  • Wild-type estrogen receptor (ERbeta1) and the splice variant (ERbetacx/beta2) are both expressed within the human endometrium throughout the normal menstrual cycle.
  • Ogawa et al. 1998. Nucleic Acids Res. 26(15):3505-12. PMID: 9671811.
  • Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor ofestrogen action in human.